Skip to main content

Table 2 Chemotherapy increases overall survival in high-risk score patients.

From: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

  High Intermediate Low
HR P value HR P value HR P value
All (2004–2009)       
 Chemotherapy (yes vs no/unknown) 0.60 (0.47, 0.77) 7.40E−05 0.74 (0.62, 0.87) 2.70E−04 0.90 (0.7, 1.15) 0.40
 Radiation (yes vs no/unknown) 1.22 (0.95, 1.56) 0.12 0.72 (0.62, 0.83) 1.40E−05 0.76 (0.65, 0.88) 2.00E−04
 Age (old vs young) 1.87 (1.37, 2.55) 7.50E−05 2.39 (1.94, 2.93) 9.36E−17 3.42 (2.75, 4.27) 1.05E−27
 Stage (Stage I as baseline)       
  Stage II 1.77 (1.35, 2.31) 3.00E−05 1.7 (1.43, 2.02) 3.00E−09 1.53 (1.29, 1.82) 1.10E−06
  Stage III 3.42 (1.62, 7.25) 1.30E−03 4.59 (2.67, 7.88) 3.40E−08 2.91 (1.39, 6.08) 4.54E−03
  Stage IV 6.68 (2.70, 16.53) 4.00E−05 9.43 (4.86, 18.31) 3.30E−11 21.58 (8.84, 52.64) 1.50E−11
 Grade (Grade I as baseline)       
  Grade II 1.26 (0.67, 2.34) 0.47 1.29 (1.05, 1.58) 0.01 1.34 (1.14, 1.58) 4.10E−04
  Grade III 1.38 (0.75, 2.54) 0.30 1.85 (1.47, 2.32) 1.40E−07 1.28 (0.98, 1.66) 0.07
 Lymph node (+ vs −) 1.8 (1.23, 2.64) 2.30E−03 1.07 (0.82, 1.39) 0.64 1.08 (0.83, 1.4) 0.56
ER+HER2(2010–2015)       
 Chemotherapy (yes vs no/unknown) 0.62 (0.47, 0.82) 7.70E−04 0.79 (0.66, 0.95) 0.01 0.73 (0.52, 1.01) 0.06
 Radiation (yes vs no/unknown) 0.84 (0.64, 1.09) 0.19 0.7 (0.59, 0.83) 3.30E−05 0.77 (0.66, 0.89) 4.20E−04
 Age (old vs young) 1.37 (0.98, 1.93) 0.07 2.69 (2.07, 3.5) 1.70E−13 3.71 (2.85, 4.82) 1.17E−22
 Stage (Stage I as baseline)       
  Stage II 1.56 (1.15, 2.11) 3.97E−03 1.44 (1.17, 1.77) 6.60E−04 1.48 (1.24, 1.77) 2.10E−05
  Stage III 5.60 (3.05, 10.29) 2.60E−08 2.44 (1.45, 4.11) 7.70E−04 2.86 (1.77, 4.61) 1.70E−05
  Stage IV 11.59 (5.82, 23.07) 3.10E−12 19.49 (10.76, 35.28) 1.03E−27 14.44 (7.36, 28.33) 8.10E−15
 Grade (Grade I as baseline)       
  Grade II 1.83 (0.74, 4.53) 0.19 1.13 (0.9, 1.42) 0.29 1.1 (0.94, 1.3) 0.24
  Grade III 1.99 (0.81, 4.85) 0.13 1.86 (1.45, 2.39) 1.10E−06 1.31 (1.01, 1.69) 0.05
 Lymph node (+ vs −) 1.37 (0.97, 1.93) 0.08 1.41 (1.11, 1.79) 4.88E−03 1.06 (0.85, 1.32) 0.59
ER+HER2+ (2010–2015)       
 Chemotherapy (yes vs no/unknown) 0.48 (0.19, 1.25) 0.13 0.5 (0.15, 1.66) 0.26 0.61 (0.13, 2.81) 0.53
 Radiation (yes vs no/unknown) 0.68 (0.26, 1.76) 0.42 0.33 (0.1, 1.08) 0.07 0.61 (0.21, 1.77) 0.37
 Age (old vs young) 3.75 (0.5, 28.38) 0.20 NA NA NA NA
 Stage (Stage I as baseline)       
  Stage II 1.28 (0.45, 3.59) 0.64 0.33 (0.04, 2.64) 0.30 0.69 (0.15, 3.19) 0.63
  Stage III 2.55 (0.23, 28.81) 0.45 0 (0, Inf) 1.00 0 (0, Inf) 1.00
  Stage IV 7.08 (0.68, 73.70) 0.10 NA NA 0 (0, Inf) 1.00
 Grade (Grade I as baseline)       
  Grade II NA NA 3.32 (0.41, 26.98) 0.26 1.04 (0.32, 3.42) 0.95
  Grade III NA NA 3.62 (0.4, 33.04) 0.25 0.75 (0.08, 6.82) 0.80
 Lymph node (+ vs −) 1.03 (0.26, 4.13) 0.96 4.26 (0.38, 47.95) 0.24 1.33 (0.18, 9.81) 0.78